

以 ADC 創新 驅動次世代價值創造

股東大會

June 26, 2026

Safe Harbor Statement

This presentation contains certain forward-looking statements.

These forward-looking statements may be identified by words such as “believes,” “expects,” “anticipates,” “projects,” “intends,” “should,” “seeks,” “estimates,” “future,” “or similar expressions or by discussion of, among other things, strategy, goals, plans, or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others:

1. Pricing and product initiatives of competitors
2. Legislative and regulatory developments and economic conditions
3. Delay or inability in obtaining regulatory approvals or bringing products to market
4. Fluctuations in currency exchange rates and general financial market conditions
5. Uncertainties in the discovery, development, or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products
6. Increased government pricing pressures
7. Interruptions in production
8. Loss of or inability to obtain adequate protection for intellectual property rights
9. Litigation
10. Loss of key executives or other employees
11. Adverse publicity and news coverage

OBI Pharma cautions that this foregoing list of factors is not exhaustive. There may also be other risks that management is unable to predict at this time that may cause actual results to differ materially from those in forward-looking statements. **You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. OBI undertakes no obligation to update publicly or revise any forward-looking statements.**

Any statements regarding earnings growth is not a profit forecast and should not be interpreted to mean that OBI’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed published earnings or earnings per share forecasts of OBI Pharma, Inc.

議程

陳雅琪 藥學博士
代理執行長暨研發長



- 公司定位 & 目標
- 核心技術與創新產品線
- 浩鼎價值與未來藍圖

台灣浩鼎

從ADC平台創新走向全球授權

以次世代創新 ADC 為核心的**精準癌症新藥** 研發公司



獨家平台

OBRION® 平台
次世代 ADC 鍵結技術



差異化資產

首創 / 同類最佳
ADC 產品線



授權價值

國際商業合作契機

整合型領導力以創造價值

執行團隊



陳雅琪 藥學博士
代理執行長暨研發長



Dong Xu 博士
醫務長 (USA)



高國霖 會計師
營運長



Jukka Muhonen
執行處長, 商務處 (USA)



董事會




梁廣義 博士
董事長



蔣永芳 博士
副董事長


全球 ADC 創新浪潮加速，國際藥廠持續擴大布局

年複合成長率 (CAGR) 達 87.5%



Obrion® 核心技術與競爭優勢

Obrion®以四項核心技術，系統性解決傳統ADC的異質性、穩定性與小分子藥物設計限制



已進入臨床驗證 (美國, 台灣)

非靶點毒性下降

經驗證的高產率 GMP 製造

突破 DAR 限制

雙藥可達 DAR 24 / 單藥可達 DAR 16

GlycOBI®

專一位點糖鍵結平台
維持抗體結構完整性與製程彈性

GlycOBI DUO®

次世代雙藥ADC糖鍵結平台
精準調控雙藥鍵結比例

HYPPrOBI®

親水且穩定之連接子設計

EndoSymeOBI®

雙功能專利酵素

Enzyme Manufacturing

Next-Generation ADC Technology Platform



Obrion Engine™
OBI Enzyme technology



- ✓ Proven Manufacturing Capabilities
- ✓ ADC Enabling Technologies
- ✓ Out-licensing Opportunities
- ✓ Specialized Personnel

Enzyme Production

- Total Capacity: 60L
- 600ml – 10,000mL
- 2 X 5 L,
- 1 X 50 L (Target 2027)
- ISO 17025 (Target 2026)




Contact Us: service@obipharma.com  +886-2-2655-8799

酵素生產整合

全方位自主製造確保品質一致性、量產擴展性與快速 ADC 開發能力

Downstream process room




Reagent preparation room



Upstream process room



Washing room



技術平台驅動多資產開發

強化產品線策略

→ 外部引進

→ 研究合作



OBI-902: 臨床一期進行中

美國




- Scripps Green Hospital
- MD Anderson Cancer Center
- NEXT Oncology

台灣



- 雙和醫院
- 中國醫學大學附設醫院
- 萬芳醫院

已收案癌種包含



N=3

6
mg/kg

N=3+3

4.5
mg/kg

N=3

3
mg/kg

N=1

1.6
mg/kg

目前於六處試驗中心
合計收案 13 位病人

OBI-201 克服“GATE”的雙靶點 TROP2 x HER2設計

加強 藥物靶點傳送

強化 癌症專一性

針對 HER2低表現
或抗藥性之病人

Enhertu[®] successor



 **ENHERTU[®]**
trastuzumab deruxtecan

~\$5B USD in 2025



CAGR 17.6%



HER2-positive
(IHC 3+) 8.7%



OBI-221: Enabled by Glyc OBI DUO®

全球首創雙抗雙藥ADC：於胃腸道癌及非小細胞肺癌展現高度治療潛力

以生物學機制為基礎的
雙靶點策略
克服治療抗藥性




USD 67億

USD 142.5億

2026 癌症藥物市場

透過雙階段攻擊機制
實現最大化腫瘤殺傷效果



浩鼎的價值路徑




ADC 藥物價值

- 產品商業授權
- 藥物達里程碑或商業化銷售



平台價值

- 連接子及小分子藥物等偶聯技術之授權合作



專利酵素價值

- 有效利用產能，創造現金流營收








策略研發合作

- 共同研發，推動產品進度及擴展臨床發展，達成風險共攤的戰略聯盟

浩鼎躋身全球 ADC 創新重要企業之列

唯一受列雙藥 ADC 技術平台的開發公司

May 2026

NEWS CATEGORY	DISCOVERY/ PRECLINICAL	PHASE 1	PHASE 2	PHASE 3/ APPROVED	Company	ADCs		
						Asset	Target	Payload
 REGULATORY	       		    		Blenrep	BCMA	TUBi	
				 	PADCEV	Nectin-4	TUBi	
					BL-B01D1	EGFR/HER3	Topo1i	
				 	SYS6051			
 CLINICAL	  	   		HS-20093				
			 	SKB315				
			 	ESG406				
				IPN60300				
 CORPORATE	 		 		GLR1059			
				 	Datroway			
					PF-08046037			
				 	CKD-703			
 DEALS	 		 		ADCE-T02	TF	Topo1i	
					Sofetabart	Mipitecan	Fra	Topo1i
				 	9MW2821	Nectin-4	Topo1i	
					CT-P70/71/73	C-MET/Nectin-4	Topo1i	
						BL-M07D1	HER2	Topo1i
PLATFORM								
						HYProtecan/Obrion Engine		

關於 Pheno
專注於提供
市場分析與
際專業顧問

關於 Phenomiqs:
專注於提供深具影響力的
市場分析與策略指引的國
際專業顧問機構

永續發展目標藍圖



短期目標

- 加速平台技術與核心資產之全球商業授權
- 深耕次世代 ADC 藥物開發與新型藥物 (Payload)
- 全面擴充並強化多元產品線



中期目標

- 持續驅動專有平台技術之升級
- 推進次世代ADC全球臨床試驗與生物製品許可申請 (BLA)



長期目標

- 晉升為具備成功開發全球重磅炸彈級藥物 (Blockbuster Drug) 實力之創新型國際生技製藥企業

Thank you

